NEW YORK, Aug. 20 – Proteome Systems and the Buck Institute for Age Research have agreed to jointly study proteins involved in aging using Proteome Systems' proteomics technologies, the company said on Monday.
The groups, which will conduct their studies using mice and C. elegans worms, plan to identify proteins in the mitochondria of brain cells involved in oxidative stress and aging, Mary Lopez, Proteome Systems' executive vice president of proteomics R&D in the US, told GenomeWeb .
“We’re going to be focusing on mitochondrial proteins, but we won’t be limited to that," Lopez said. "Our primary goal is to identify proteins involved in the aging process, with the eventual goal of identifying drug targets.”
To do this, Lopez’s team will study samples provided by the Buck Institute to identify as many or all of the proteins in the mitochondria of brain cells, and will perform differential protein expression studies of samples taken from organisms of various ages and states of neurological disease.
Lopez, who will lead Proteome Systems’ portion of the project, said the Buck Institute partnership had been under discussion for about a year. She did not disclose financial details. Proteome Systems will conduct a one-year pilot project, and the Buck Institute, based in Novato, Calif., has the option to extend the partnership by two years, Lopez said.
Proteome Systems will employ its prefractionation, 2D gel electrophoresis, and mass spectrometry analysis techniques to analyze and identify the proteins in the Buck Institute research. Lopez said the research will take place primarily at the Buck Institute, based in Novato, Calif., and in Proteome Systems’ Boston facility.
In addition to conducting its own proteomics research, Proteome Systems will release later this year a platform of 2D gel electrophoresis instrumentation, sample preparation kits, and equipment for mass spectrometry analysis of proteins in partnership with Sigma and Kratos Analytical, a subsidiary of Shimadzu Biotech.In June, Proteome Systems, which has offices in Sydney, Australia, and Boston, established a similar, smaller-scale collaboration with researchers at the University of Missouri-Columbia to study the proteins involved in resistance to cancer drugs.